摘要
目的 解析度洛西汀在中国的专利概况,为国内制药企业制定研发战略提供参考。方法 运用定性和定量分析方法,对1987至2012年间度洛西汀在中国的专利信息进行统计处理,得出结论。结果与结论 度洛西汀虽无化合物专利,但具有药品行政保护,并具有一系列剂型、晶型、工艺和组方专利,保护期限各不相同,我国仿制企业需认真研究,以制定有效的研发策略。
Abstract
OBJECTIVE To find out the patent situation of duloxetine and provide references for domestic pharmaceutical companies to establish appropriate R&D strategies. METHODS The patent situation of duloxetine in China, such as the numbers of applications,distribution, the applicants, legal status, patent contents etc. during the year of 1987--2012 are statistically analyzed by METHODS of quantitative and qualitative analysis. RESULTS AND CONCULSION Duloxetine has administrative protection but no compound patent in China. Although the number of valid patents is not very high, but we still need to pay attention to patents of crystal and method to avoid infringement.
关键词
抗抑郁药 /
度洛西汀 /
专利分析
{{custom_keyword}} /
Key words
antidepressant drug /
duloxetine /
patent analysis
{{custom_keyword}} /
于培明,李俊丽,温祁.
抗抑郁药度洛西汀专利现状分析[J]. 中国药学杂志, 2014, 49(19): 1770-1772 https://doi.org/10.11669/cpj.2014.19.025
YU Pei-ming,LI Jun-li,WEN Qi.
Analysis for Current Situation of Patents of Duloxetine[J]. Chinese Pharmaceutical Journal, 2014, 49(19): 1770-1772 https://doi.org/10.11669/cpj.2014.19.025
中图分类号：
F204
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] MA P Q. Duloxetine hydrochloride in the treatment of chronic musculoskeletal pain has been approved by FDA [J]. Shanghai Med Pharm J(上海医药),2011,32(1):31.[2] DuloxetineHydrochloride.[EB/OL].[2013-06-01]. http://baike.baidu.com/view/1651266.htm.[3] Top20 Best-Selling Drugs of 2012.[EB/OL]. [2013-9-24]http://www.genengnews.com/insight-and-intelligence/top-20-best-selling-drugs-of-2012/77899775/ page=2,2013-03-05.[4] YANG P,GU D L,MA S P. Analysis of the current situation of the patents of statins in China[J]. Chin New Drugs J(中国新药杂志),2011,20(5):404-406.[5] BIAN Z J,ZHANG H,ZHOU J. Analysis of present situation of patent protection of atorvastatin [J].Chin Inv Patent(中国发明与专利), 2011(10):44-49.[6] PENG J X, YANG Y G. A study on patent protection and market monopoly in United States[J].Chin J Med Guide(中国医药导刊),2007,9(6):524-525.[7] DING J X. A study on drug patent prolonging system in the US the Enlightenment of Hatch-Waxman Act to China’s pharmaceutical industry [J].Chin J Pharm(中国医药工业杂志),2006,37(9):113-117.[8] DING J X,LI X J. A study on protection strategy of crystal Patent based on the empirical analysis of patent invalidation case of crystal patent of adefovir dipivoxil[J].China Inv Patent(中国发明与专利),2012(8):40-45.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(754 KB)
